IRON
−$50.8K
941 sh @ $54
ORBIMED ADVISORS LLC
Director, 10% Owner · SEC CIK 1055951
Insider at
STTK Shattuck Labs, Inc.
QTTB Q32 Bio Inc.
SION Sionna Therapeutics, Inc.
TRAW Traws Pharma, Inc.
PRLD Prelude Therapeutics Inc
IMA ImageneBio, Inc.
ACET Adicet Bio, Inc.
KROS Keros Therapeutics, Inc.
PMVP PMV Pharmaceuticals, Inc.
TSBX Turnstone Biologics Corp.
IKNA ImageneBio, Inc.
CRVS Corvus Pharmaceuticals, Inc.
PASG Passage BIO, Inc.
NPCE NeuroPace Inc
XTNT Xtant Medical Holdings, Inc.
CMPX Compass Therapeutics, Inc.
EWTX Edgewise Therapeutics, Inc.
IRON Disc Medicine, Inc.
MBX MBX Biosciences, Inc.
Advertisement
Buy track record
How this insider's open-market purchases have performed52%
of buys now in profit
12 up · 11 down
Avg return since buy+65.7%
Median return+5.8%
Best trade+397.0%
Worst trade−79.6%
Buys scored23
Average return by holding period — separates good entry timing from riding one long winner
After 1 month
+11.0%
43% won · 21 trades
After 3 months
−7.1%
22% won · 18 trades
After 6 months
+25.5%
44% won · 18 trades
After 12 months
+79.5%
50% won · 14 trades
| Date | Company | 90d trend | Buy price | Value | ΔOwn | 1M | 3M | 6M | 12M | To date |
|---|---|---|---|---|---|---|---|---|---|---|
| May 28, 2026 | QTTB | $8 | $10M | +55% | — | — | — | — | +22.6% | |
| May 28, 2026 | QTTB | $8 | $5M | NEW | — | — | — | — | +22.6% | |
| Apr 21, 2026 | PRLD | $4 | $7.5M | +17% | −6.3% | — | — | — | −2.8% | |
| Apr 21, 2026 | PRLD | $4 | $5M | NEW | −6.3% | — | — | — | −2.8% | |
| Apr 16, 2026 | TRAW | $2 | $998.2K | +99% | +45.5% | — | — | — | +5.8% | |
| Oct 8, 2025 | ACET | $1 | $1.5M | +20% | −29.3% | −45.6% | −55.9% | — | −45.8% | |
| Oct 8, 2025 | ACET | $1 | $3.5M | +353% | −29.3% | −45.6% | −55.9% | — | −45.8% | |
| Aug 25, 2025 | STTK | $1 | $4.56M | NEW | +130.4% | +102.2% | +307.4% | — | +397.0% | |
| Aug 25, 2025 | STTK | $1 | $912K | NEW | +130.4% | +102.2% | +307.4% | — | +397.0% | |
| Apr 3, 2025 | EWTX | $20 | $7.5M | +2.6% | +21.8% | −4.1% | +15.2% | +141.8% | +156.5% | |
| Apr 3, 2025 | EWTX | $20 | $2.5M | +39% | +21.8% | −4.1% | +15.2% | +141.8% | +156.5% | |
| Feb 18, 2025 | MBX | $11 | $531.9K | +1.5% | −22.8% | +11.5% | +33.7% | +269.8% | +225.8% | |
| Feb 18, 2025 | MBX | $11 | $1.02M | +14% | −22.8% | +11.5% | +33.7% | +269.8% | +225.8% | |
| Feb 14, 2025 | MBX | $10 | $177.8K | +0.6% | −16.4% | −2.3% | +26.9% | +278.3% | +241.1% | |
| Feb 14, 2025 | MBX | $10 | $291K | +0.9% | −16.4% | −2.3% | +26.9% | +278.3% | +241.1% | |
| Feb 10, 2025 | SION | $18 | $9.9M | +17% | −33.0% | −42.0% | −9.9% | +70.9% | +61.5% | |
| Jan 25, 2024 | ACET | $2 | $4.42M | +32% | −2.0% | −26.7% | −38.9% | −63.2% | −79.6% | |
| Jan 25, 2024 | ACET | $2 | $581.3K | +32% | −2.0% | −26.7% | −38.9% | −63.2% | −79.6% | |
| Jan 25, 2024 | ACET | $2 | $2.5M | +486% | −2.0% | −26.7% | −38.9% | −63.2% | −79.6% | |
| Jun 27, 2023 | ACET | $2 | $261.3K | +14% | +17.4% | −32.4% | −17.4% | −37.1% | −76.4% | |
| Jun 27, 2023 | ACET | $2 | $522.5K | +63% | +17.4% | −32.4% | −17.4% | −37.1% | −76.4% | |
| Jun 27, 2023 | ACET | $2 | $923.8K | +8.4% | +17.4% | −32.4% | −17.4% | −37.1% | −76.4% | |
| Jun 27, 2023 | ACET | $2 | $121.2K | +8.4% | +17.4% | −32.4% | −17.4% | −37.1% | −76.4% |
How this is calculated. We score only open-market purchases (SEC code
P) — the buys that carry real signal. Each trade's return is measured from the adjusted closing price on the purchase date to the latest close, accounting for stock splits and dividends. The 1M/3M/6M/12M columns show the same trade's return after each fixed holding period; a dash means that horizon hasn't elapsed yet or isn't priceable. Sales are excluded because insiders sell for many routine reasons. With only 23 scored trades, treat this as a small sample, not a verdict.
Advertisement
Open-market buys
$70.22M
23 trades
Open-market sells
$114.54M
78 trades
Net flow
−$44.32M
Net selling
Total filings
106
transactions shown
Full transaction history
All Form 4 activity across every company, newest firstIRON
−$78.7K
1,457 sh @ $54
IRON
−$19.7K
364 sh @ $54
IRON
−$730.2K
13,517 sh @ $54
IRON
−$1.13M
20,911 sh @ $54
Advertisement
IRON
−$282.4K
5,228 sh @ $54
IRON
−$33.2K
603 sh @ $55
IRON
−$51.4K
933 sh @ $55
IRON
−$12.8K
233 sh @ $55
IRON
−$1.51M
27,750 sh @ $54
IRON
−$2.34M
42,930 sh @ $54
IRON
−$584.3K
10,733 sh @ $54
IRON
−$498.1K
9,222 sh @ $54
IRON
−$770.6K
14,267 sh @ $54
IRON
−$192.7K
3,567 sh @ $54
IRON
−$3.73M
68,766 sh @ $54
IRON
−$5.78M
106,384 sh @ $54
IRON
−$1.44M
26,596 sh @ $54
IRON
−$7.5K
136 sh @ $55
IRON
−$11.6K
211 sh @ $55
IRON
−$2.9K
53 sh @ $55
MBX
Orbimed Advisors Llc, MBX's 10% owner, spent $531.9K of their own money on 49,070 shares at $11, growing their stake 2%.
+$531.9K
49,070 sh @ $11
MBX
Orbimed Advisors Llc, MBX's 10% owner, spent $1.02M of their own money on 94,100 shares at $11, growing their stake 14%.
+$1.02M
94,100 sh @ $11
MBX
Orbimed Advisors Llc, MBX's 10% owner, spent $177.8K of their own money on 17,962 shares at $10, growing their stake 1%.
+$177.8K
17,962 sh @ $10
MBX
Orbimed Advisors Llc, MBX's 10% owner, spent $291K of their own money on 29,540 shares at $10, growing their stake 1%.
+$291K
29,540 sh @ $10
SION
+$0
3.15M sh
SION
Orbimed Advisors Llc, SION's Director, spent $9.9M of their own money on 550,000 shares at $18, growing their stake 17%.
+$9.9M
550,000 sh @ $18
PASG
−$47.4K
79,024 sh @ $1
PASG
−$11.5K
17,986 sh @ $1
PASG
−$83.3K
126,209 sh @ $1
Frequently asked questions
How is ORBIMED ADVISORS LLC's win rate calculated?
We take every open-market purchase (SEC code P) we can match to a stock price, then compare the split- and dividend-adjusted price on the purchase date to the most recent close. The win rate is the share of those buys currently trading above the purchase price. Sales and share grants are not scored.
Why are some buys not included in the score?
A purchase is excluded if we can't price it — for example if the ticker is missing from the filing, the company has been delisted, or the security isn't a common stock we can match to market data. Excluded counts are shown next to the scored total.
What do the 1M / 3M / 6M / 12M columns mean?
They show each purchase's return after a fixed holding period — one, three, six, and twelve months from the buy date — using split- and dividend-adjusted prices. This separates good entry timing from simply holding a long-running winner. A dash means that horizon hasn't elapsed yet for that trade, or the stock couldn't be priced at that date.
Does a high win rate mean I should copy this insider?
No. Past performance does not predict future results, sample sizes are often small, and an insider's edge in their own company doesn't transfer to yours. This is context, not a recommendation. InsiderSource is not investment advice.
Where does this data come from?
Trades come from ORBIMED ADVISORS LLC's SEC Form 4 filings on EDGAR. Prices come from public market data and are split/dividend-adjusted. Always verify against the original filings before acting.